Mubadala Capital

Activity from announced rounds

Activity in this selectioncape-fear-biocapital-89f4b680
Rounds participated in
4
Confirmed lead rounds
1
3 roles undisclosed
New companies
4
First participation on record · 0 follow-on
Funding in participating rounds
$403.5M
3 disclosed · full round size, not this investor’s share

By stage

Series B2
Series C+2

By primary sector

Biotech3
AI1

By country

United States4

Rounds

4 in this selection
Crusoe

AI infrastructure combining GPU cloud services, managed AI tools, large-scale data centers and modular AI factories for model developers and enterprises.

>$3.9BSeries F
Lead
Ollin Biosciences

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries B
Role not disclosed
Alloy Therapeutics

Provides AI-powered platforms and integrated services for drug discovery and development

$40MSeries E
Role not disclosed